Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Frias

Endocrinology, Diabetes & Metabolism San Diego, CA Medical Doctor

NPI 1134437601 CMS profile 142836

5011 Sterling Grove Ln, San Diego, CA 92130

Open in the dashboard

General payments

$1,439,591

1,111 records reported · program years 2019–2025

Research payments

$824,542

Paid to them · 101 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,691,154 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Juan Frias of San Diego, CA is reported in the CMS Open Payments database as having received $1,439,591 across 1,111 general payments and $824,542 in research payments paid to them. Separately, studies naming them as principal investigator received $12,691,154 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,501 12
2025 Research $1,250 1
2024 General $639 12
2024 Research $1,500 4
2023 General $229,744 238
2023 Research $7,521 20
2022 General $293,344 253
2022 Research $20,235 20
2021 General $184,403 84
2021 Research $2,500 2
2020 General $163,738 89
2020 Research $466,044 28
2019 General $557,222 423
2019 Research $325,492 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Frias
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Juan Frias were reported at $10,501. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Juan Frias Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $557,222 $494 $123–$2,253 $163
2020 $163,738 $335 $85–$1,841 $114
2021 $184,403 $398 $88–$1,981 $132
2022 $293,344 $364 $88–$1,568 $149
2023 $229,744 $420 $113–$1,614 $160
2024 $639 $440 $121–$1,646 $164
2025 $10,501 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $743,073 328 payments
  2. Lilly USA, LLC $220,202 316 payments
  3. Merck Sharp & Dohme Corporation $154,038 165 payments
  4. Novo Nordisk Inc $74,163 77 payments
  5. LifeScan, Inc. $66,785 48 payments
  6. Novo Nordisk AS $58,631 30 payments
  7. Eli Lilly and Company $52,694 85 payments
  8. Echosens North America, Inc. $15,895 9 payments
  9. Corcept Therapeutics $11,698 10 payments
  10. Hikma Pharmaceuticals USA $10,326 9 payments
  11. Other $32,087 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $745,784 248 payments
  2. Consulting Fee $371,418 132 payments
  3. Travel and Lodging $293,827 441 payments
  4. Food and Beverage $16,954 254 payments
  5. Honoraria $9,385 6 payments
  6. Education $2,222 30 payments
Products named General payments · program years 2019–2025
  1. SOLIQUA 100/33 Endocrine & Metabolic Diseases $251,318 74 payments
  2. SOLIQUA 100/33 Diabetes $184,245 108 payments
  3. MOUNJARO $172,311 199 payments
  4. TOUJEO $152,170 91 payments
  5. LANTUS $91,421 23 payments
  6. SOLIQUA 100/33 Endocrinology $87,190 33 payments
  7. STEGLATRO $62,775 87 payments
  8. Victoza $34,910 14 payments
  9. NO PRODUCT DISCUSSED $30,705 12 payments
  10. AMARYL $27,785 8 payments
  11. Other $256,714 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Allergan Inc. $712,580 15 payments
  2. Eli Lilly and Company $75,042 39 payments
  3. Sanofi-Aventis U.S. LLC $18,526 29 payments
  4. Pfizer Inc. $9,680 5 payments
  5. Regeneron Pharmaceuticals, Inc. $3,987 3 payments
  6. Sanofi US Services Inc. $2,900 1 payment
  7. Corcept Therapeutics $920 5 payments
  8. Novo Nordisk AS $908 4 payments

Records

1,212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record